Anzeige
Mehr »
Freitag, 08.08.2025 - Börsentäglich über 12.000 News
Das Kupferangebot bricht ein - und dieser neue Fund kommt genau zur richtigen Zeit
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C6GM | ISIN: FR0014005OJ5 | Ticker-Symbol: N/A
Frankfurt
15.10.24 | 15:29
0,746 Euro
0,00 % 0,000
1-Jahres-Chart  (nicht börsennotiert)
ACTICOR BIOTECH SA Chart 1 Jahr

Aktuelle News zur ACTICOR BIOTECH

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.03.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 06.03.2025590The following instruments on Boerse Frankfurt do have their last trading day on 06.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 06.03.2025ISIN NameFR0014005OJ5 ACTICOR...
► Artikel lesen
06.03.XFRA CAPITAL ADJUSTMENT INFORMATION - 06.03.2025256Das Instrument 7V7 FR0014005OJ5 ACTICOR BIOTECH EO 1 EQUITY wird cum Kapitalmassnahme gehandelt am 06.03.2025 und ex Kapitalmassnahme am 07.03.2025 The instrument 7V7 FR0014005OJ5 ACTICOR BIOTECH EO...
► Artikel lesen
06.01.Acticor Biotech announces its liquidation proceedings344Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced...
► Artikel lesen
19.12.24Acticor Biotech Announces that the Court Judgment Has Been Postponed Until January 2, 2025315Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced...
► Artikel lesen
10.12.24Acticor Biotech Announces the Filing of a Request for Conversion of Receivership Proceedings Into Liquidation Proceedings396Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced...
► Artikel lesen
10.12.24XFRA 7V7: AUSSETZUNG/SUSPENSION183DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILACTICOR BIOTECH...
► Artikel lesen
ACTICOR BIOTECH Aktie jetzt für 0€ handeln
06.11.24Acticor Biotech Provides an Update on the Current Receivership Proceedings439Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today...
► Artikel lesen
04.11.24Acticor Biotech Publishes Its Half-year Financial Results for 2024706Acticor Biotech publishes its half-year financial results for 2024 Repositioning of glenzocimab in the treatment of ST-segment elevation myocardial infarction (STEMI) Receivership proceedings:...
► Artikel lesen
16.10.24Acticor Biotech: Extension of the Call for Tenders With a View to a Restructuring Plan or Sale Under the Receivership Procedure370Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today...
► Artikel lesen
14.10.24Acticor Biotech appoints François Guillet as Chief Financial Officer368Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today...
► Artikel lesen
11.10.24Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial Infarction47227 patients recruited in the phase 2b LIBERATE study evaluating glenzocimab in the treatment of ST-Elevation Myocardial Infarction (STEMI) Preparation of a new phase 2 study, GLORIA, evaluating...
► Artikel lesen
03.10.24Acticor Biotech: Extension of the Receivership Procedure402Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces...
► Artikel lesen
16.09.24XFRA 7V7: WIEDERAUFNAHME/RESUMPTION199FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
12.09.24Acticor Biotech Launches a Call for Tenders to Provide a Continuation or Sale Plan as Part of the Receivership Procedure502Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten